WALNUT CREEK, CA, USA & SUZHOU, CHINA, April 27, 2026

Dark Horse Consulting Group (DHCG) and Porton Advanced have announced a strategic Memorandum of Understanding (MOU) to streamline the pathway for conducting Investigator-Initiated Trials (IITs) in China, marking a significant advancement in global clinical development infrastructure for cell and gene therapies. This collaboration aims to accelerate clinical translation, reduce regulatory complexity, and enhance manufacturing readiness, providing biopharma sponsors with a more efficient route to initiate clinical programs in one of the world’s fastest-growing healthcare markets.

Strategic Collaboration to Accelerate Clinical Trials

The partnership combines DHCG’s deep expertise in regulatory strategy, clinical development, and quality compliance with Porton Advanced’s end-to-end GMP manufacturing capabilities, creating a fully integrated solution for advanced therapy developers. This includes support across CMC, nonclinical, clinical, supply chain, and commercialization stages, enabling seamless progression from early development to clinical execution.

A key focus of the collaboration is enabling faster and more efficient IITs in China, where regulatory navigation and local manufacturing requirements often present significant barriers. By aligning international regulatory expectations with China’s National Medical Products Administration (NMPA) standards, the partnership offers sponsors a streamlined approach to entering the Chinese clinical landscape.

Enhancing GMP Manufacturing and Regulatory Integration

Advertisement

cGxPJobs Banner

Porton Advanced brings robust GMP-compliant infrastructure, including capabilities in lentiviral vectors, AAV, mRNA/LNP, plasmids, and engineered cell therapies such as CAR-T and CAR-NK, positioning the collaboration at the forefront of advanced therapy manufacturing. With over 24 IND clearances and support for more than 30 IITs, Porton Advanced demonstrates a strong track record in enabling global clinical programs.

The integration of DHCG’s consulting expertise ensures that sponsors can effectively navigate complex regulatory frameworks while maintaining compliance with global GxP standards, reducing delays often caused by misalignment between manufacturing and regulatory processes. This unified approach is expected to shorten timelines to first-in-human studies and improve overall development efficiency.

Driving Innovation in Cell and Gene Therapy Development

This MOU reflects a broader industry shift toward integrated development models that combine consulting, manufacturing, and regulatory expertise to accelerate innovation, particularly in the rapidly evolving field of cell and gene therapy. China’s growing importance as a clinical research hub makes it a strategic priority for global developers seeking to expand their pipelines and access diverse patient populations.

By reducing friction at the manufacturing–regulatory interface, the DHCG–Porton Advanced collaboration enables sponsors to advance therapies with greater speed, confidence, and cost efficiency, ultimately supporting faster delivery of life-saving treatments to patients. The partnership also highlights the increasing demand for cross-border clinical development solutions that align global standards with local regulatory requirements.

Source: Dark Horse Consulting Group press release